Vemurafenib Terminated Phase 2 Trials for Active Melanoma Brain Metastases Treatment

IndicationsStatusPurposePhase
TerminatedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02230306Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases